ProCE Banner Events

Share

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care

Expert nurse practitioner and physician associate faculty will discuss the latest advances and potential with the CDK4/6 inhibitors for HR-positive/HER2-negative breast cancer care.

Nurse Practitioners: 2.00 Nursing contact hours, includes 2.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 2.00 AAPA Category 1 CME credits

Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with HR+/HER2- breast cancer.

Time and location

Saturday, January 18, 2025

12:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Faculty
Jamie L. Carroll, APRN, CNP, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Elizabeth Diaz, PA-C

Physician Assistant
Medical Oncology
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California

Agenda

  • Welcome and Introductions
  • Fundamentals I: Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC
  • Skill Building and Feedback I: Role-Play and Patient Counseling on EBC Assessment and Treatment
  • Reflection and Commitment to Practice Change I
  • Fundamentals II: Individualizing Therapy for HR-Positive/HER2-Negative MBC
  • Skill Building and Feedback II: Role-Play and Patient Counseling on MBC Assessment and Treatment
  • Reflection and Commitment to Practice Change II
  • Fundamentals III: Addressing AEs and Adherence Challenges
  • Skill Building and Feedback III: Role-Play and Patient Counseling on AEs and Adherence
  • Reflection and Commitment to Practice Change III
  • Final Thoughts and Audience Question and Answer Session

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer.

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with HR+/HER2- breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the role of risk assessment and biomarkers in guiding optimal therapy selection in patients with HR+/HER2- EBC and MBC
  • Create individualized strategies for adjuvant therapy in patients with high-risk, HR+/HER2- EBC, considering tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
  • Formulate treatment plans for sequencing therapy in patients with HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
  • Apply recommended strategies to improve patient recognition of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer and to monitor and manage the AEs appropriately
  • Initiate discussions with patients to identify and address challenges to adherence and persistence with oral therapies targeting CDK4/6

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hour of pharmacotherapy credits.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.